Thymic carcinoma
Conditions
Interventions
WT-1 pulsed dendritic cell immunotherapy
Sponsors
Fukushima Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with advanced/recurrent thymic carcinoma who have previously been treated with at least one chemotherapy regimen 2) Aged 20 to 75 years 3) Performance status (ECOG) 0-1 4) Patients don't have been joined any other trials 5) Patients providing written informed consent 6) Adequate organ function 7) HBV Ag, HCV Ag, HTLV1, HIV, syphilis negative 8) Patients who have one of the following HLA types: A2402, A0201, A0206
Exclusion criteria
Exclusion criteria: 1) Patients with active concomitant malignancy 2) Patients have allergy for OK-432 or penicillin 3) With uncontrollable hypertension or diabetes 4) With angina pectoris or myocardial infarction 5) With uncontrollable heart failure or cerebrovascular disorder 6) With pulmonary fibrosis or interstitial pneumonia 7) With bleeding ulcer, intestinal obstruction 8) With Immunosuppressive agent or predonine 9) With severe allergy disease 10) With autoimmune disease 11) With myelodysplastic syndrome 12) Pregnancy or lactation. 13) Patients with mental disorder, and considered as inappropriate for the study by the physicians 14) Physician concludes that the patient's participation in this trial is inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival(OS), response rate, delayed type hypersensitivity, ELISPOT assay, tetramer assay | — |
Countries
Japan
Contacts
Public ContactHiroyuki Suzuki
Fukushima Medical University Chest Surgery
Outcome results
None listed